MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.